Actualités

In May 2026, Exelixis announced extensive upcoming presentations at the ASCO Annual Meeting, highlighting new CABOMETYX data and pivotal zanzalintinib trials across multiple hard-to-treat cancers. These data, alongside a new Merck collaboration on the STELLAR-316 phase 3 colorectal cancer trial using MRD-guided enrollment, underscore Exelixis’ push to extend its oncology footprint beyond CABOMETYX. We’ll now assess how this expanded zanzalintinib program, especially the STELLAR-303 and...

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

In addition to developing the vaccine for measles, mumps and rubella, Hilleman's pioneering breakthroughs include hepatitis A and B.

The United States market has shown robust performance with a 2.5% increase over the last week and a remarkable 26% rise in the past year, while earnings are projected to grow by 17% annually. In this thriving environment, identifying stocks that may be trading below their estimated value can offer compelling opportunities for investors seeking to capitalize on potential growth at attractive prices.

ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.

On May 26, 2026, Micron’s surge helped propel the S&P 500 and Nasdaq to fresh records even as the Dow lagged.

AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.

Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.

The Dow gave back its opening gains, with healthcare stocks a big drag. The blue-chip index was trading flat, while the S&P 500 was up 0.9%, and the Nasdaq rose 1.4%. UnitedHealth Group and Amgen, among the Dow's top five stocks, were down by nearly 3% and 0.4%, respectively.

Wall Street closed higher on Friday, driven by defensive stocks and falling bond yields.

A Minnesota jury has found Merck and several cosmetic talc manufacturers liable in a mesothelioma lawsuit. The verdict centers on claims that Dr. Scholl's-branded talc products were defective and unreasonably dangerous. The case resulted in one of the largest personal injury awards related to cosmetic talc in Minnesota history. For investors watching NYSE:MRK, this verdict introduces a fresh source of legal scrutiny that sits outside the company’s core pharmaceutical and oncology focus. The...

All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.

Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.

Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.

Merck (NYSE:MRK) reported positive Phase 3 results for its antibody drug conjugate sacituzumab tirumotecan in advanced endometrial cancer and in lung cancer combinations. The company said sacituzumab tirumotecan surpassed standard chemotherapy in advanced endometrial cancer, a first for an ADC in this setting. Merck also highlighted that KEYTRUDA combination regimens received key regulatory recommendations in the EU for frontline perioperative use in muscle invasive bladder cancer. For...

Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT) met its dual primary endpoints of overall survival/OS and progression-free survival/PFS in patients with advanced or recurrent endometrial cancer. The investigational TROP2-directed […]

Investing.com -- The United States has suspended visa issuance for any travelers who have visited South Sudan, the Democratic Republic of Congo (DRC), or Uganda within 21 days of their planned arrival, according to an exclusive report by The Wall Street Journal on Friday.

The healthcare sector outperformed the rest of the market over the past week.

US equity indexes rose as pressure on government bond yields eased and crude oil retreated from intr

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.42%. June E-mini S&P futures (ESM26 ) rose +0.35%, and June E-mini Nasdaq futures...

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index advancing 0.8% and the State

US equity indexes rose as pressure on government bond yields eased and crude oil retreated from intr

The S&P 500 Index ($SPX ) (SPY ) today is up +0.50%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.73%. June E-mini S&P futures (ESM26 ) are up +0.47%, and June E-mini Nasdaq futures...

Merck's Gardasil sales plunge as weak China demand, inventory issues and softer Japan trends cloud the vaccine's overall growth outlook in 2026.

Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.

Merck’s KEYTRUDA + Padcev Bladder Cancer Combination Edges Closer To EU Approval.